Debt-to-equity of Cytek Biosciences, Inc. from 31 Mar 2022 to 31 Dec 2025

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Cytek Biosciences, Inc. quarterly Debt-to-equity in % history and change rate from 31 Mar 2022 to 31 Dec 2025.
Cytek Biosciences, Inc. Debt-to-equity for the quarter ending 31 Dec 2025 was 31%, a 19% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

Cytek Biosciences, Inc. Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q4 2025	31%	+5%	+19%	31 Dec 2025
Q3 2025	29%	+2.9%	+11%	30 Sep 2025
Q2 2025	28%	+2.7%	+11%	30 Jun 2025
Q1 2025	26%	+1.3%	+5.2%	31 Mar 2025
Q4 2024	26%	+1.2%	+5%	31 Dec 2024
Q3 2024	26%	+2%	+8.6%	30 Sep 2024
Q2 2024	25%	+2.7%	+12%	30 Jun 2024
Q1 2024	25%	+3.5%	+16%	31 Mar 2024
Q4 2023	25%	+4.3%	+21%	31 Dec 2023
Q3 2023	24%	+5.3%	+29%	30 Sep 2023
Q2 2023	22%	+5.9%	+35%	30 Jun 2023
Q1 2023	21%	+2%	+10%	31 Mar 2023
Q4 2022	20%			31 Dec 2022
Q3 2022	18%			30 Sep 2022
Q2 2022	17%			30 Jun 2022
Q1 2022	19%			31 Mar 2022

* An asterisk sign (*) next to the value indicates that the value is likely invalid.